A Randomized, double blind study to determine the effect of two dose schedules of R1507 or placebo, both in combination with erlotinib (Tarceva®), on progression-free survival in patients with advanced non-small cell lung cancer with disease progression after first or second line chemotherapy To define the proportion of patients with PFS at 12 weeks with the combination of R1507 and erlotinib or a corresponding placebo and erlotinib in patients with advanced Stage IIIB/IV Non-Small Cell Lu...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A study to measure a blood protein, asthma-related biological molecules and response to prednisolone in adult and young patients with severe oral corticosteroid-dependent asthma •To evaluate the levels of serum periostin in a population of patients with severe OCS-dependent asthma at Baseline • To examine the stability of serum periostin levels and individual patient phenoty...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Study of RoActemra/Actemra (tocilizumab) in Comparison to Enbrel (etanercept) in Patients With Rheumatoid Arthritis and Increased Risk for Heart Disease Composite of major adverse cardiovascular events (MACE) consisting of cardiovascular death, non-fatal myocardial infarction and non-fatal stroke of all classifications

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A 52 week, Single center, Open-label Study to Evaluate Neutrophil function and survival effects of Tocilizumab (TCZ) in Patients with Active Rheumatoid Arthritis (RA) on Background Non-biologic DMARDs who have an Inadequate Response to Current Non-biologic DMARD and/or Anti-TNF Therapy To assess the mechanisms of TCZ effects on neutrophil function and survival.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Open-label study of bevacizumab (AVASTIN®) in combination with platinum-containing chemotherapy as first-line treatment of patients with advanced or recurrent non-squamous non-small cell lung cancer To assess the safety profile of bevacizumab when combined with standard chemotherapy as first-line treatment of advanced or recurrent non-squamous NSCLC. In particular, the incidence of serious advers...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Study Evaluating the Efficacy and Safety of Lebrikizumab in Adult Patients with Mild to Moderate Asthma •To evaluate the efficacy of lebrikizumab compared with placebo in improving lung function, as measured by the absolute change in pre-bronchodilator forced expiratory volume in 1 second (FEV1), in adu...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A multicentre, open-label, randomized, phase III study to evaluate the efficacy of Tarceva™ or comparator Alimta® (pemetrexed) or Taxotere® (docetaxel) in patients with histologically documented, advanced or recurrent (stage IIIB and not amenable for combined modality treatment) or metastatic (Stage IV) non-small cell lung cancer who have experienced disease progression during platinum-based chemotherapy To determine if the administration of Tarceva™ after disease progression on standard platinum-based chemotherapy in the treatment of NSCLC results in improved overall survival when compared to Alimta®...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Phase III, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study, Evaluating the Safety, Tolerability and Efficacy of RO4607381 by Measuring Flow Mediated Dilatation in the Brachial Artery, 24 hour Ambulatory Blood Pressure, Lipids, Lipoproteins and Markers Vascular Inflammation, Oxidation and CV risk in Patients with Coronary Heart Disease (CHD) or CHD Risk Equivalents The primary efficacy objective of this study is to evaluate the effect of RO4607381 on endothelial function as measured by flow mediated dilatation (FMD) of the brachial artery in patients with CHD or...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

An open-label, randomized, multicenter, parallel group study to demonstrate correction of anemia using intravenous injections of RO0503821 in patients with chronic kidney disease who are on dialysis To demonstrate the efficay of IV RO 0503821

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Phase III Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Emicizumab in Hemophilia A Pediatric Patients With Inhibitors Estudio Fase III para evaluar la Eficacia, Seguridad y Farmacocinética de Emicizumab en pacientes pediatricos con hemofilia A con inhibidores There is no formal hypothesis testing in the study. Efficacy ? To evaluate clinical effect of prophylactic emicizumab on number of bleeds over time (bleed rate) ? To characterize efficacy of up-titrat...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune